Editas Medicine, Inc. (EDIT)

Lumos Pharma Operating Expense Breakdown

Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016
Research and Development	199.25M	220.19M	213.07M	188.63M	177.65M	160.09M	160.91M	174.79M
Research and Development Growth	12.16%	37.54%	32.41%	7.92%	1.54%	-0.26%	8.39%	26.16%
General and Administrative	71.99M	70.09M	66.99M	65.98M	69.65M	73.18M	74.43M	74.17M
General and Administrative Growth	3.35%	-4.23%	-10.00%	-11.03%	-1.49%	5.69%	7.57%	-0.16%

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.